HCAIX-IN-23

Product Specifications

Target

Carbonic Anhydrase|||Apoptosis|||Ferroptosis|||Reactive Oxygen Species|||Caspase|||Mitochondrial Metabolism

Related Pathways

Immunology/Inflammation|||NF-?B|||Metabolism|||Apoptosis|||Proteases/Proteasome

Bioactivity

HCAIX-IN-23 (Compound 27) is a human carbonic anhydrase (hCA) inhibitor with Ki values of 10.4 nM for hCA IX and 8.5 nM for hCA XII. It not only inhibits hCA activity but also releases NO, exerting dual anti-tumor effects. By reducing the expression of hCA IX and iron regulatory proteins, hCAIX-IN-23 regulates mitochondrial caspase activity and the ferroptosis pathway, thereby inducing apoptosis. This compound is utilized in research focused on renal cancer.